|
Jun 12
|
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
|
|
Jun 10
|
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
|
|
Apr 22
|
Cytokinetics to Announce First Quarter Results on May 6, 2025
|
|
Apr 22
|
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
|
|
Apr 15
|
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
|
|
Apr 15
|
Bristol Myers stumbles in bid to widen heart drug’s use
|
|
Apr 14
|
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
|
|
Apr 11
|
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
|
|
Mar 1
|
Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 28
|
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
|
|
Feb 28
|
Q4 2024 Cytokinetics Inc Earnings Call
|
|
Feb 28
|
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses
|
|
Feb 27
|
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 27
|
Cytokinetics: Q4 Earnings Snapshot
|
|
Feb 27
|
Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update
|
|
Feb 23
|
Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 20
|
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now
|
|
Nov 12
|
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
|
|
Nov 11
|
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
|
|
Nov 8
|
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations
|